Roche Holding Ltd - Nov 2, 2021 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role: 10%+ Owner
Signature: /s/ Jared Cohen, as Attorney-in-Fact
Stock symbol: TRDA
Transactions as of: Nov 2, 2021
Transactions value $: $0
Form type: 4
Date filed: 11/4/2021, 09:45 PM
Previous filing: Oct 28, 2021
Next filing: Jan 26, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TRDA	Common Stock	Conversion of derivative security		+2.5M			2.5M	Nov 2, 2021	See Footnote	F1, F2
transaction	TRDA	Common Stock	Conversion of derivative security		+318K	+12.75%		2.81M	Nov 2, 2021	See Footnote	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TRDA	Series A Preferred Stock	Conversion of derivative security	$0	-2.5M	-100%	$0.00^*	0	Nov 2, 2021	Common Stock	2.5M		See Footnote	F1, F2
transaction	TRDA	Series B Preferred Stock	Conversion of derivative security	$0	-318K	-100%	$0.00^*	0	Nov 2, 2021	Common Stock	318K		See Footnote	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.
F2	Represents shares held by Roche Finance Ltd ("Roche Finance"). Roche Finance is a wholly owned subsidiary of Roche Holding Ltd ("Roche Holding"), a Swiss corporation whose shares are traded on the SIX Swiss Exchange. Roche Holding is the indirect beneficial owner of these securities of the Issuer. This Form 4 shall not be deemed an admission that any reporting person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4.

Content

Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

Represents shares held by Roche Finance Ltd ("Roche Finance"). Roche Finance is a wholly owned subsidiary of Roche Holding Ltd ("Roche Holding"), a Swiss corporation whose shares are traded on the SIX Swiss Exchange. Roche Holding is the indirect beneficial owner of these securities of the Issuer. This Form 4 shall not be deemed an admission that any reporting person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4.